» Articles » PMID: 35288636

Hospitalization Rates from Radiotherapy Complications in the United States

Overview
Journal Sci Rep
Specialty Science
Date 2022 Mar 15
PMID 35288636
Authors
Affiliations
Soon will be listed here.
Abstract

Hospitalizations due to radiotherapy (RT) complications result in significant healthcare expenditures and adversely affect the quality of life of cancer patients. Using a nationally representative dataset, the objective of this study is to identify trends in the incidence of these hospitalizations, their causes, and the resulting financial burden. Data from the National Inpatient Sample was retrospectively analyzed from 2005 to 2016. RT complications were identified using ICD-9 and ICD-10 external cause-of-injury codes. The hospitalization rate was the primary endpoint, with cost and in-hospital death as secondary outcomes. 443,222,223 weighted hospitalizations occurred during the study period, of which 482,525 (0.11%) were attributed to RT. The 3 most common reasons for RT-related hospitalization were cystitis (4.8%, standard error [SE] = 0.09), gastroenteritis/colitis (3.7%, SE = 0.07), and esophagitis (3.5%, SE = 0.07). Aspiration pneumonitis (1.4-fold) and mucositis (1.3-fold) had the highest relative increases among these hospitalizations from 2005 to 2016, while esophagitis (0.58-fold) and disorders of the rectum and anus were the lowest (0.67-fold). The median length of stay of patient for hospitalization for RT complications was 4.1 (IQR, 2.2-7.5) days and the median charge per patient was $10,097 (IQR, 5755-18,891) and the total cost during the study period was $4.9 billion. Hospitalization for RT-related complications is relatively rare, but those that are admitted incur a substantial cost. Use of advanced RT techniques should be employed whenever possible to mitigate the risk of severe toxicity and therefore reduce the need to admit patients.

Citing Articles

Radioprotection of healthy tissue via nanoparticle-delivered mRNA encoding for a damage-suppressor protein found in tardigrades.

Kirtane A, Bi J, Rajesh N, Tang C, Jimenez M, Witt E Nat Biomed Eng. 2025; .

PMID: 40011582 DOI: 10.1038/s41551-025-01360-5.


Out of field scatter from electron applicator in modern linear accelerators.

Sengupta B, DeFillippo G, Sohn J, Yadav P, Das I J Appl Clin Med Phys. 2024; 25(6):e14265.

PMID: 38335230 PMC: 11163494. DOI: 10.1002/acm2.14265.


UCHL1 Regulates Radiation Lung Injury via Sphingosine Kinase-1.

Epshtein Y, Mathew B, Chen W, Jacobson J Cells. 2023; 12(19).

PMID: 37830619 PMC: 10572187. DOI: 10.3390/cells12192405.


Efficacy and safety of transarterial chemoembolization with CalliSpheres® Microspheres in head and neck cancer.

Gao F, Gao J, Wang K, Song L Front Surg. 2022; 9:938305.

PMID: 36090318 PMC: 9452835. DOI: 10.3389/fsurg.2022.938305.

References
1.
Jairam V, Lee V, Park H, Thomas Jr C, Melnick E, Gross C . Treatment-Related Complications of Systemic Therapy and Radiotherapy. JAMA Oncol. 2019; 5(7):1028-1035. PMC: 6583836. DOI: 10.1001/jamaoncol.2019.0086. View

2.
Du X, Chan W, Giordano S, Geraci J, Delclos G, Burau K . Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer. 2005; 104(5):913-24. PMC: 2566845. DOI: 10.1002/cncr.21271. View

3.
Wong W, Yim Y, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P . Assessment of costs associated with adverse events in patients with cancer. PLoS One. 2018; 13(4):e0196007. PMC: 5898735. DOI: 10.1371/journal.pone.0196007. View

4.
Halpern M, Yabroff K . Prevalence of outpatient cancer treatment in the United States: estimates from the Medical Panel Expenditures Survey (MEPS). Cancer Invest. 2008; 26(6):647-51. DOI: 10.1080/07357900801905519. View

5.
Wong J, Evans S . Bacterial Pneumonia in Patients with Cancer: Novel Risk Factors and Management. Clin Chest Med. 2017; 38(2):263-277. PMC: 5424613. DOI: 10.1016/j.ccm.2016.12.005. View